Brought to you by 
Auxilium takes a license to Vivus' Stendra; rights returned
07 Oct 2016
Executive Summary
Vivus Inc. (mainly sexual health and metabolic and respiratory conditions) granted Auxilium Pharmaceuticals Inc. (urology, endocrinology, and musculoskeletal therapeutics) exclusive US and Canadian marketing rights to Stendra (avanafil), an FDA-approved oral erectile dysfunction (ED) treatment.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Auxilium takes a license to Vivus' Stendra; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice